News

The director of the Movement Disorders Clinic at Houston Methodist Hospital discussed the distinct features, progression, and clinical implications of psychosis in Parkinson disease. [WATCH TIME: 4 minutes]

Following positive phase 3 findings, Apnimed plans to submit a new drug application to the FDA in early 2026 for its lead candidate AD109 as a potential treatment of obstructive sleep apnea.

The movement disorder neurologist at University of Rochester Medical Center outlined a 5-pillar model that emphasized holistic care, patient-centered communication, and proactive support in movement disorders. [WATCH TIME: 5 minutes]

Overviewing the major clinical trial readouts in neurology from the first half of 2025, with data that could potentially reshape patient care.

The professor of psychology at Avila University discussed how cognitive behavioral therapy and social support can help to improve quality of life for individuals with Parkinson disease. [WATCH TIME: 4 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

The chief program officer at PMD Alliance discussed the value of combining experiential learning and holistic care strategies to support advanced therapeutics in Parkinson disease. [WATCH TIME: 4 minutes]

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on the ATMRD Congress.

A recent analysis reveals significant links between sleep, quality of life, and daily activities in patients with Parkinson disease, highlighting benefits of Vyalev treatment.

Daniel Irizarry, MD, a former physician and patient living with PD, discussed how hands-on simulation training could enhance clinician empathy and improve treatment strategies.

Continuous subcutaneous apomorphine infusion enhances confidence and reduces treatment burden for Parkinson's patients, improving daily activity engagement.

Neurology News Network. for the week ending June 28, 2025. [WATCH TIME: 4 minutes]

Cynthia Fox, PhD, CCC-SLP, CEO and co-founder of LSVT Global, discussed the evolution of rehabilitative therapies in PD and stressed early referrals for speech, physical, and occupational therapy.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 27, 2025.

UCB has recently announced promising phase 3 trial results of fenfluramine, a potential new treatment to enhance seizure control for CDKL5 deficiency disorder.

The design of a phase 2 study, presented at ATMRD 2025, highlighted the trial’s patient-focused approach, allowing patients with Parkinson disease to complete visits either at home or in a clinic.

The medical advisor at Tactical Medical Solutions shared insights from both clinical and personal perspectives on the importance of empathy and active listening in managing Parkinson disease. [WATCH TIME: 3 minutes]

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Joseph Sullivan, MD. [LISTEN TIME: 14 minutes]

A recent survey reveals critical gaps in neurology training on women's health, highlighting the need for urgent curriculum reforms in medical education.

New findings reveal eptinezumab significantly reduces migraine days and medication use in chronic migraine patients, offering hope for effective treatment.

The assistant professor in the Department of Neuroscience at Université de Montréal discussed the importance of weighing the risks of multiple sclerosis against treatment risks, emphasizing individualized care. [WATCH TIME: 4 minutes]

Chia-Chun Chiang, MD, associate professor of neurology at Mayo Clinic Rochester, discussed how AI-based ECG and imaging tools can aid in predicting stroke and cardiovascular outcomes in patients with migraine.

New data reveals vidofludimus calcium effectively maintains low disability progression in relapsing-remitting multiple sclerosis over 144 weeks, enhancing patient quality of life.

The consultant neurologist at Torbay and Southern Devon Healthcare NHS Foundation Trust discussed the implementation of digital platforms and lifestyle-focused clinics to streamline MS care. [WATCH TIME: 5 minutes]

Grace Therapeutics submits NDA for GTx-104, a promising IV treatment for aSAH, aiming to revolutionize patient care and improve outcomes.

The chair of neurology at the University of South Carolina discussed findings from a study recently presented at AHS 2025 that linked migraine to autonomic dysfunction, increased risk of atrial fibrillation, and cardioembolic stroke. [WATCH TIME: 5 minutes]

The professor of neurology at the Geisel School of Medicine at Dartmouth broke down the clinical utility, supporting data, and practical use cases for STS101, a newly approved nasal powder formulation of dihydroergotamine for acute migraine.

The FDA expands Vizamyl's use for Alzheimer diagnosis and therapy monitoring, enhancing patient care with precise amyloid quantification.

Skyhawk Therapeutics initiates FALCON-HD trial for SKY-0515, a promising treatment for Huntington disease, aiming to modify disease progression.

The postdoctoral researcher at the Woolcock Institute of Medical Research highlighted EEG-based evidence supporting ALKS 2680's wake-promoting effects in patients with narcolepsy and idiopathic hypersomnia. [WATCH TIME: 3 minutes]